{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:25:30Z","timestamp":1792632330048,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T00:00:00Z","timestamp":1721779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Production of large amounts of functional NK and CAR-NK cells represents one of the bottlenecks for NK-based immunotherapy. In this study, we developed a large-scale, reliable, and practicable NK and CAR-NK production using G-Rex 100M bioreactors, which depend on a gas-permeable membrane technology. This system holds large volumes of medium with enhanced oxygen delivery, creating conditions conducive to large-scale PBNK and CAR-NK expansions for cancer therapy. Both peripheral blood NK cells (PBNKs) and CAR-NKs expanded in these bioreactors retained similar immunophenotypes and exhibited comparable cytotoxicity towards hepatocellular carcinoma (HCC) cells akin to that of NK and CAR-NK cells expanded in G-Rex 6 well bioreactors. Importantly, cryopreservation minimally affected the cytotoxicity of NK cells expanded using the G-Rex 100M bioreactors, establishing a robust platform for scaled-up NK and CAR-NK cell production. This method is promising for the development of \u201coff-the-shelf\u201d NK cells, supporting the future clinical implementation of NK cell immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1412378","type":"journal-article","created":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:56:47Z","timestamp":1721797007000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Scalable process development of NK and CAR-NK expansion in a closed bioreactor"],"prefix":"10.3389","volume":"15","author":[{"given":"Xuening","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeve Elizabeth","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minh Tuyet","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,7,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Frey","year":"2016","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.06.009","article-title":"Control of metastasis by NK cells","volume":"32","author":"Lopez-Soto","year":"2017","journal-title":"Cancer Cell"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3390\/biomedicines10071493","article-title":"Alternative CAR therapies: recent approaches in engineering chimeric antigen receptor immune cells to combat cancer","volume":"10","author":"Moreno","year":"2022","journal-title":"Biomedicines"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discovery"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s13238-017-0415-5","article-title":"Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV","volume":"8","author":"Liu","year":"2017","journal-title":"Protein Cell"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.12810","article-title":"CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell Malignancies","volume":"20","author":"Romanski","year":"2016","journal-title":"J Cell Mol Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat Commun"},{"key":"B11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-021-01083-5","article-title":"Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy","volume":"14","author":"Gong","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"611163","DOI":"10.3389\/fimmu.2020.611163","article-title":"Engineering NK cells for CAR therapy-recent advances in gene transfer methodology","volume":"11","author":"Schmidt","year":"2020","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"11075","DOI":"10.1038\/s41598-017-09259-1","article-title":"Expansion of cytotoxic natural killer cells using irradiated autologous peripheral blood mononuclear cells and anti-CD16 antibody","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.802906","article-title":"Feeder cells at the interface of natural killer cell activation, expansion and gene editing","volume":"13","author":"Gurney","year":"2022","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"14015","DOI":"10.1038\/mtm.2014.15","article-title":"Optimizing the production of suspension cells using the G-Rex \"M\" series","volume":"1","author":"Bajgain","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-16104-4_15","article-title":"Peripheral blood mononuclear cells","volume-title":"The Impact of Food Bioactives on Health: in vitro and ex vivo models","author":"Kleiveland","year":"2015"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07667.x","article-title":"Replicative potential of human natural killer cells","volume":"145","author":"Fujisaki","year":"2009","journal-title":"Br J Haematol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-3712","article-title":"Expansion of highly cytotoxic human natural killer cells for cancer cell therapy","volume":"69","author":"Fujisaki","year":"2009","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00879","article-title":"Expansion of human NK cells using K562 cells expressing OX40 ligand and short exposure to IL-21","volume":"10","author":"Kweon","year":"2019","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"119960","DOI":"10.1016\/j.biomaterials.2020.119960","article-title":"A three-dimensional hyaluronic acid-based niche enhances the therapeutic efficacy of human natural killer cell-based cancer immunotherapy","volume":"247","author":"Ahn","year":"2020","journal-title":"Biomaterials"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.06.014","article-title":"Superior expansion and cytotoxicity of human primary NK and CAR-NK cells from various sources via enriched metabolic pathways","volume":"18","author":"Yang","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.01.020","article-title":"Immunological synapse predicts effectiveness of chimeric antigen receptor cells","volume":"26","author":"Xiong","year":"2018","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.01.011","article-title":"Molecular mechanisms of functional natural killer deficiency in patients with partial DiGeorge syndrome","volume":"135","author":"Zheng","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.803380","article-title":"Feeder-cell-free and serum-free expansion of natural killer cells using cloudz microspheres, G-rex6M, and human platelet lysate","volume":"13","author":"Johnson","year":"2022","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1412378\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,24]],"date-time":"2024-07-24T04:56:51Z","timestamp":1721797011000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1412378\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,24]]},"references-count":25,"alternative-id":["10.3389\/fimmu.2024.1412378"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1412378","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,24]]},"article-number":"1412378"}}